GPT Healthcare Limited Q2 profit rises 45% to Rs 15.40 crore

GPT Healthcare Limited reported profit after tax of Rs 15.40 crore for the quarter ended September 30, 2026, up 45% from Rs 10.60 crore a year earlier, while revenue from operations increased 14% to Rs 135.62 crore. The Board approved the unaudited results on November 5, 2026, and declared a Re 1 interim dividend per share.

How did GPT Healthcare perform in the September 2026 quarter?

GPT Healthcare’s revenue from operations rose by Rs 16.71 crore year on year to Rs 135.62 crore in the quarter ended September 30, 2026, from Rs 118.91 crore in the corresponding quarter of 2025. Other income increased to Rs 2.94 crore from Rs 1.34 crore, taking total income to Rs 138.57 crore from Rs 120.25 crore.

GPT Healthcare’s profit before tax increased to Rs 20.68 crore from Rs 15.07 crore, while total tax expense rose to Rs 5.27 crore from Rs 4.47 crore. Profit after tax consequently increased by Rs 4.80 crore to Rs 15.40 crore, compared with Rs 10.60 crore in the September 2025 quarter.

GPT Healthcare reported basic and diluted earnings per share of Rs 1.88 for the September quarter, against Rs 1.29 in the prior-year quarter. The company marked both quarterly figures as not annualised. Total comprehensive income was Rs 15.35 crore, compared with Rs 10.59 crore a year earlier, after other comprehensive loss of Rs 5.56 lakh.

What changed in GPT Healthcare’s costs and profitability?

GPT Healthcare’s total expenses increased by Rs 12.71 crore to Rs 117.89 crore in the September 2026 quarter, from Rs 105.18 crore a year earlier. The rise was smaller than the Rs 18.32 crore increase in total income, and profit before tax rose by Rs 5.61 crore over the same comparison.

Other expenses remained the largest reported cost line at Rs 59.53 crore, up from Rs 53.68 crore in the September 2025 quarter. Cost of materials consumed increased to Rs 25.93 crore from Rs 22.19 crore, employee benefits expense rose to Rs 23.29 crore from Rs 20.01 crore, and depreciation and amortisation rose to Rs 7.05 crore from Rs 6.35 crore.

GPT Healthcare’s finance costs declined to Rs 2.10 crore from Rs 2.16 crore a year earlier. Sequentially, revenue from operations rose from Rs 126.20 crore in the quarter ended June 30, 2026, while profit after tax increased from Rs 12.73 crore and profit before tax rose from Rs 17.16 crore.

What do GPT Healthcare’s half-year results and cash flows show?

GPT Healthcare reported revenue from operations of Rs 261.83 crore for the half year ended September 30, 2026, compared with Rs 226.02 crore in the corresponding six months of 2025. Half-year profit before tax rose to Rs 37.84 crore from Rs 26.18 crore, and profit after tax increased to Rs 28.13 crore from Rs 18.29 crore.

GPT Healthcare’s first-half total income was Rs 266.80 crore, including other income of Rs 4.97 crore, compared with total income of Rs 228.92 crore and other income of Rs 2.90 crore a year earlier. Total expenses rose to Rs 228.96 crore from Rs 202.73 crore, with materials cost at Rs 50.08 crore and employee benefits expense at Rs 46.52 crore.

GPT Healthcare generated net operating cash flow of Rs 34.23 crore in the half year, compared with Rs 33.65 crore in the prior-year period. Cash generated from operations before working-capital changes increased to Rs 52.64 crore from Rs 40.65 crore, but the increase in trade receivables used Rs 12.57 crore, versus Rs 8.80 crore a year earlier.

GPT Healthcare used Rs 16.49 crore in investing activities during the six months, compared with Rs 22.75 crore in the previous corresponding period. Purchases of property, plant and equipment, intangible assets and capital work in progress totalled Rs 18.27 crore, while investment purchases were Rs 14.23 crore; net financing cash outflow was Rs 20.96 crore, against Rs 11.09 crore a year earlier.

What does GPT Healthcare’s balance sheet and dividend decision show?

GPT Healthcare’s total assets stood at Rs 480.07 crore at September 30, 2026, compared with Rs 464.75 crore at March 31, 2026. Total equity increased to Rs 285.19 crore from Rs 269.43 crore, including other equity of Rs 203.13 crore, up from Rs 187.37 crore at the previous financial year-end.

GPT Healthcare’s property, plant and equipment was Rs 264.76 crore at September 30, compared with Rs 265.44 crore at March 31. Capital work in progress increased to Rs 8.08 crore from Rs 7.07 crore, trade receivables rose to Rs 31.64 crore from Rs 20.28 crore, and cash and cash equivalents fell to Rs 91.38 lakh from Rs 4.33 crore.

GPT Healthcare’s Board declared an interim dividend of 10%, equivalent to Re 1 per fully paid equity share with a face value of Rs 10, for financial year 2026-27. The record date is November 12, 2026, and GPT Healthcare expects payment on or before December 4, 2026. The company reported no subsidiary, associate or joint venture at September 30, and its statutory auditor issued an unmodified conclusion on the limited review.

Conclusion

GPT Healthcare’s September-quarter results showed profit after tax increasing faster than operating revenue, with profit rising Rs 4.80 crore to Rs 15.40 crore and revenue increasing Rs 16.71 crore to Rs 135.62 crore. The half-year figures also showed profit after tax of Rs 28.13 crore and operating cash flow of Rs 34.23 crore, while trade receivables increased by Rs 11.36 crore from March 31.

The next disclosed event is the November 12, 2026 record date for the Re 1 per-share interim dividend, which GPT Healthcare expects to pay by December 4, 2026. Future results will indicate whether the Rs 261.83 crore first-half operating revenue growth continues and whether receivables, at Rs 31.64 crore on September 30, change further.